BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bayer AG (BAY.F) Walks Away From Schiff After Reckitt Benckiser Plc (RB.L) Trumps Bid


11/20/2012 7:12:25 AM

Bayer AG (BAYN) decided not to raise its takeover offer for Schiff Nutrition International Inc. (SHF), yielding to Reckitt Benckiser Group Plc’s (RB/) $1.4 billion counterbid for the U.S. vitamin maker. The price would have been too high, the Leverkusen, Germany-based company today in a filing with the Securities and Exchange Commission. Bayer said Oct. 30 it had agreed to buy Salt Lake City-based Schiff for about $1.1 billion, or $34 a share. Reckitt began an unsolicited tender offer for Schiff Nov. 16 at $42 a share. Reckitt’s higher bid foiled Bayer Chief Executive Officer Marijn Dekkers’s attempt to add faster-growing vitamins and supplements to Bayer’s consumer-health unit. Schiff makes Move Free joint-care pills, Tiger’s Milk nutrition bars, MegaRed Omega-3 supplements and the Airborne cold-prevention remedy. “This is a very good and very reasonable move,” Fabian Wenner, an analyst at Kepler Capital Markets in Zurich, said in a telephone interview today. “The higher price would have eaten a good part of the expected synergies.” Investors, anticipating a higher bid from Bayer or another company, had pushed Schiff shares above the Reckitt offer price. The stock rose 0.9 percent to close at $44.15 yesterday in New York Stock Exchange composite trading. Reckitt rose 0.7 percent to 3,805 pence at 12:50 p.m. in London, while Bayer gained 0.1 percent to 66.48 euros.

Read at Bloomberg
Read at Reuters
Read at CBS News
Read at EconomicTimes


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->